Regeneron Pharmaceuticals SEC filings, summarized
We read every Regeneron Pharmaceuticals 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track REGN in your inbox
Add Regeneron Pharmaceuticals to your watchlist — free, every morning.
Recent filings
Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year…
Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year 2025 financial & operating results; Exhibit 104 =…
Regeneron ($REGN) issued a press release on Jan 30, 2026 announcing financial & operating results for the…
Regeneron ($REGN) issued a press release on Jan 30, 2026 announcing financial & operating results for the quarter and year ended Dec 31, 2025. Press release…
Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S.
Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S. Schleifer and CSO George D. Yancopoulos at the 44th…
Regeneron ($REGN) on 2026-01-12 furnished a Regulation FD presentation (Exhibit 99.1) referenced in Item…
Regeneron ($REGN) on 2026-01-12 furnished a Regulation FD presentation (Exhibit 99.1) referenced in Item 2.02 — the presentation is incorporated by…
Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP…
Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP diluted EPS by ~ $0.14. Preliminary estimate…